Dasatinib, which was initially designed as a kinase inhibitor against Bcr-Abl for myeloid leukemia and gastrointestinal stromal tumors, affects a wide range of targets within the Src family kinases upstream of SFK and is known to inhibit FcγR function (38–40). Here, FCGR2A is linked to myeloid leukemia.